Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants With Chronic Rhinosinusitis With Nasal Polyps on Background Intranasal Corticosteroids

INTERVENTIONALInicio: 29 de abr de 2024ID: NCT06338995

ReclutandoClinicalTrials.gov

Prospective Study of Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients From Argentina

OBSERVATIONALInicio: 3 de dic de 2024ID: NCT07059026

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

INTERVENTIONALInicio: 4 de sept de 2024ID: NCT06528314

ReclutandoFase 4ClinicalTrials.gov

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress - The ASPIRE-AF Trial

INTERVENTIONALInicio: 14 de jun de 2019ID: NCT03968393

ReclutandoFase 3ClinicalTrials.gov

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4

INTERVENTIONALInicio: 8 de sept de 2022ID: NCT05243797

ReclutandoFase 3ClinicalTrials.gov

An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]

INTERVENTIONALInicio: 22 de may de 2025ID: NCT06962800

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

INTERVENTIONALInicio: 15 de dic de 2023ID: NCT06170788

ReclutandoFase 4ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Mucus Plugging and Other Lung Imaging Parameters in Patients With Chronic Obstructive Pulmonary Disease.

INTERVENTIONALInicio: 22 de sept de 2025ID: NCT07053423

ReclutandoFase 2ClinicalTrials.gov

A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

INTERVENTIONALInicio: 19 de dic de 2024ID: NCT06500702

ReclutandoFase 3ClinicalTrials.gov

Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)

INTERVENTIONALInicio: 11 de ago de 2025ID: NCT07099898

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

INTERVENTIONALInicio: 16 de dic de 2024ID: NCT06679101

ReclutandoFase 3ClinicalTrials.gov

Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

INTERVENTIONALInicio: 1 de abr de 2024ID: NCT06200207

ReclutandoFase 2ClinicalTrials.gov

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

INTERVENTIONALInicio: 11 de ago de 2025ID: NCT06979596

ReclutandoClinicalTrials.gov

A Two -Stage First in Human (FIH) Feasibility / Pivotal Study of the Vienna Aortic Valve SE System

INTERVENTIONALInicio: 3 de jul de 2023ID: NCT04861805

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

INTERVENTIONALInicio: 24 de oct de 2025ID: NCT06793215

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis

INTERVENTIONALInicio: 17 de jul de 2024ID: NCT06456580

ReclutandoFase 3ClinicalTrials.gov

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis

INTERVENTIONALInicio: 17 de sept de 2024ID: NCT06632444

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

INTERVENTIONALInicio: 10 de abr de 2025ID: NCT06846671

ReclutandoFase 3ClinicalTrials.gov

An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis

INTERVENTIONALInicio: 11 de dic de 2024ID: NCT05421858

ReclutandoFase 3ClinicalTrials.gov

A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)

INTERVENTIONALInicio: 31 de ago de 2023ID: NCT06016842